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-Methylchrysene has been found to be a complete
carcinogen in laboratory animals. However, the tumor
promotion effects of (
 
 
 
)-anti-5-methylchrysene-1,2-
diol-3,4-epoxide (5-MCDE) remain unclear. In the present
work, we found that 5-MCDE induced marked activator
protein-1 (AP-1) activation in Cl41 cells. 5-MCDE also
induced a marked activation of phosphatidylinositol 3-kinase
(PI-3K). Inhibition of PI-3K impaired 5-MCDE–induced AP-1
transactivation, suggesting that PI-3K is an upstream kinase
involved in AP-1 activation by 5-MCDE. Furthermore, we
found that Akt is a PI-3K downstream mediator for 5-MCDE–
5
 
induced AP-1 transactivation, whereas another PI-3K down-
stream kinase, p70
 
S6K
 
, was not involved in AP-1 activation
by 5-MCDE. Moreover, inhibition of Akt activation blocked
5-MCDE–induced activation of extracellular signal–regulated
protein kinases (ERKs) and c-Jun NH
 
2
 
-terminal kinases (JNKs),
whereas it did not affect p38K activation. Consistently,
overexpression of a dominant-negative mutant of ERK2 or
JNK1 blocked the AP-1 activation by 5-MCDE. These results
demonstrate that 5-MCDE is able to induce AP-1 activation,
and the AP-1 induction is speciﬁcally through a PI-3K/Akt–
dependent and p70
 
S6K
 
-independent pathway.
 
Introduction
 
Polycyclic aromatic hydrocarbon (PAH) pollution is an
ongoing leading environmental problem (Bostrom et al.,
2002). PAHs are formed from the incomplete combustion
of organic matter, such as coal, tobacco, petro fuels, wood,
and municipal waste (International Agency for Research on
Cancer, 1983). The carcinogenicity of PAHs has been
clearly shown in both epidemiological studies and bioassays
with laboratory animals (International Agency for Research on
Cancer, 1983). The metabolite (
 
 
 
)-anti-5-methylchrysene-
1,2-diol-3,4-epoxide (5-MCDE), one important member of
PAH, has been found to be strongly carcinogenic (Hecht et
al., 1974; Amin et al., 1991; You et al., 1994; Nesnow et al.,
1998). Similar to (
 
 
 
)-anti-benzo[a]pyrene-7,8-diol-9,10-
epoxide (B[a]PDE), 5-MCDE is the in vivo epoxide metabolite
of its parent compound 5-methylchrysene, which has been
identified in tobacco and marijuana smoke as well as gasoline
and diesel engine exhaust (Hecht et al., 1974; Lee et al.,
1976; Grimmer, 1977). Chronic applications of 5-methyl-
chrysene caused high incidences of lung cancer and skin
cancer in several animal models (Hecht et al., 1974; Amin et
al., 1991; You et al., 1994; Nesnow et al., 1998). Most of
the previous works have focused on the mutagenicity of
5-methylchrysene and found that its metabolites, especially
5-MCDE, bind covalently to the N2-guanine base in the
DNA and subsequently cause mutation (Melikian et al.,
1984; Amin et al., 1985; Hecht et al., 1987; Reardon et al.,
1987). To substantiate that 5-MCDE exposure is one of the
causative factors of lung cancer associated with cigarette
smoking, Smith et al. (2000) have demonstrated that the G
to T mutation spectrum caused by 5-MCDE in the p53
tumor suppressor gene perfectly matches the mutation
hotspots found in lung cancer patients who are cigarette
smokers. These mutagenicity studies on 5-MCDE convinc-
ingly explain the tumor initiator effects of 5-MCDE. From
animal model assays for carcinogenicity, it is well accepted
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that the mutated cell needs to undergo tumor promotion
and progression to develop into a fully-grown tumor and,
ultimately, cancer. Because 5-methylchrysene was shown to
be a complete carcinogen in the animal models (Hecht et al.,
1974; Amin et al., 1991; You et al., 1994; Nesnow et al.,
1998), it is interesting and practically important to know
whether or not 5-methylchrysene and/or better certain of its
metabolites also function as tumor-promoting agents. How-
ever, to our knowledge, the mechanisms of tumor promo-
tion effects of 5-methylchrysene and its metabolites have
been barely understood.
The tumor promotion phase is a long-term reversible pro-
cess characterized as the activation of transcription factors and
regulation of their target genes through signal transduction
pathways (Slaga and Fischer, 1983; Pitot and Dragan, 1996).
The mouse epidermal JB6 Cl41 cell line is a well-character-
ized and widely used cell culture model for tumor promotion
studies (Bernstein and Colburn, 1989; Dong et al., 1994,
1995; Huang et al., 1997a, 1998; Li et al., 1997; Watts et al.,
1998). In transformation-sensitive (P
 
 
 
) but not transforma-
tion-resistant (P
 
 
 
) JB6 cell lines, tumor promoters, such as
phorbol esters or growth factors, induce activator protein-1
(AP-1) activity and neoplastic transformation (Bernstein and
Colburn, 1989). Inhibition of AP-1 induction by TAM67 (a
transactivation domain deletion mutant of c-Jun; Brown
et al., 1993) blocks 12-
 
O
 
-tetradecanoylphorbol-13-acetate
(TPA)– and EGF-induced AP-1 transactivation and cell
transformation (Dong et al., 1997). Several other events are
also found to be required for different chemical-induced tu-
mor promotion, including activation of extracellular signal–
regulated protein kinases (ERKs), nuclear factor-
 
 
 
B, and PI-
3K (Huang et al., 1996, 1997b, 1998; Li et al., 1997; Watts
et al., 1998; Hsu et al., 2000). Importantly, this cell line is de-
rived from mouse skin; thus, the results generated from Cl41
cells will provide a strong basis for further investigation in
mouse skin, which is an important bioassay system for the
evaluation of tumor promotion in vivo (Slaga and Fischer,
1983; Pitot and Dragan, 1996). Therefore, Cl41 cells were
used in this paper as the in vitro model to investigate the
tumor-promoting activity of 5-MCDE, the metabolite of
5-methylchrysene. We found that 5-MCDE induces AP-1
transcriptional activity in the Cl41 cell line, and this induc-
tion occurs via a PI-3K/Akt–dependent signaling pathway.
 
Results
 
Induction of transactivation of AP-1 in C141 cells 
by 5-MCDE
 
AP-1 is the transcription factor demonstrated to be required
for cancer development by chemical carcinogens. AP-1 is com-
posed of a heterogeneous set of dimeric proteins, including the
members from the Jun, Fos, and ATF families (Karin et al.,
1997). Whereas Jun is expressed constitutely but activated af-
ter phosphorylation, the Fos is activated by regulation of its
protein expression (Karin et al., 1997). It has been reported
that PAHs and/or their metabolites, such as benzo[a]pyrene
(B[a]P), affect cellular signaling pathways (Parrish et al.,
1998). Therefore, we first looked at the change of AP-1 tran-
scriptional activity after 5-MCDE treatment in the P
 
 
 
1-1
cells, which are the Cl41 cell line stably transfected with AP-1
luciferase reporter. After treating P
 
 
 
1-1 cells with noncyto-
toxic dose of 5-MCDE, AP-1 transcriptional activity was in-
duced at the level similar to UVB radiation, which is a well-
known oxidative stress and skin carcinogenic factor (Fig. 1 a).
Figure 1. Induction of AP-1 activity by 5-MCDE in Cl41 cells. (a–c) 8   10
3 
P
 1-1 cells were seeded into each well of a 96-well plate. After being cultured at 
37 C overnight, cells were treated with 1  M 5-MCDE or 0.5 KJ/m
2 UVB radiation 
for 12 h (a), various concentrations of 5-MCDE as indicated for 12 h (b), or 1  M 
5-MCDE or 5-methylchrysene for various periods of time as indicated (c). The 
luciferase activity was measured and the results are presented as AP-1 transcription 
activity relative to control (relative AP-1 activity). Each bar indicates the mean 
and SD of three repeat assay wells. (d) Cl41 cells were seeded into 6-well plates. 
The media were replaced with 0.1% FBS MEM after the cell density reached 
70–80% confluency. 45 h later, the cells were incubated with fresh serum-free MEM for 3–4 h at 37 C. Cells were exposed to 1  M 5-MCDE 
for 420 min. The cells were washed once with ice-cold PBS and extracted with SDS-sample buffer. The cell extracts were separated on 
polyacrylamide–SDS gels, transferred, and probed with one of the specific antibodies as indicated. The protein band specific bound with 
primary antibodies was detected by using anti–rabbit IgG-AP-linked and ECF Western blotting system. 
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5-MCDE–induced AP-1 transactivation appeared in a dose-
and time-dependent manner (Fig. 1, b and c). In contrast with
the AP-1 activation by 5-MCDE, 5-methylchrysene did not
show any inductive effect on AP-1 activity in Cl41 cells (Fig.
1 c). Further studies showed that at 7 h after treatment,
5-MCDE did increase in expression of AP-1 family members,
including c-Jun, Jun B, Jun D, Fra-1, Fra-2, and Fos B (Fig. 1
d), whereas it did not affect these protein’s expression at 3 h af-
ter treatment (not depicted). In contrast with these inductions,
5-MCDE did not induce c-Fos protein expression at all the
time points tested (Fig. 1 d and not depicted). More impor-
tantly, c-Jun phosphorylations at serine63 and serine73 were
markedly induced by 5-MCDE treatment (Fig. 1 d). To test
whether or not 5-MCDE is able to induce AP-1 target gene
expression, we evaluated the effects of 5-MCDE on expression
of a few AP-1 target genes, such as collagenase type I
(
 
MMP13
 
) and cyclin D1. As shown in Fig. 2, AP-1 target
genes, cyclin D1 and collagenase type I, were significantly in-
duced by 5-MCDE exposure. These results indicate that
5-MCDE, a major metabolite of 5-methylchrysene, is able to
induce AP-1 activation and AP-1 target gene expression.
 
Induction of PI-3K activity in C141 cells by 5-MCDE
 
AP-1 activity may be regulated through various signaling
pathways. Previous works have indicated that PI-3K activa-
tion is required for AP-1 activation by EGF (Huang et al.,
1996), TPA (Huang et al., 1997b), or IL-1 (Sizemore et al.,
1999). In contrast, some other works showed that PI-3K is
not involved in AP-1 activation by lipopolysaccharide, onco-
genic 70Z Cb1, and activated MEK, even though PI-3K is ac-
tivated by lipopolysaccharide or MEK (Treinies et al., 1999;
van Leeuwen et al., 1999; Guha and Mackman, 2002). Thus,
AP-1 activation could be activated via PI-3K–dependent or
–independent pathways. To elucidate the upstream signals re-
sponsible for induction of AP-1 activity by 5-MCDE, the ac-
tivity of PI-3K was measured in C141 cells. As shown in Fig.
3, treatment of cells with 5-MCDE led to marked PI-3K acti-
vation at 20 min after exposure. This result reveals that PI-3K
is activated in Cl41 cells in response to 5-MCDE exposure.
 
PI-3K activation is required for AP-1 transactivation 
by 5-MCDE in C141 cells
 
Because the aforementioned results suggested that both AP-1
and PI-3K are activated in Cl41 cells in response to 5-MCDE
exposure, it was of interest to determine the feasible role of PI-
3K in 5-MCDE–stimulated AP-1 transactivation in C141
cells. We first assessed the effects of two PI-3K chemical in-
hibitors, wortmannin and Ly294002, on 5-MCDE–induced
AP-1 activation. The results showed that unsaturated doses of
both wortmannin and Ly294002 did reduce the AP-1 activa-
tion by 5-MCDE (Fig. 4 a). To further prove the role of PI-
3K in 5-MCDE–induced AP-1 activation, Cl41 AP-1 
 
 
 
p85
mass1, which is a stable transfectant of a dominant-negative
mutant p85 subunit of PI-3K (
 
 
 
p85), was used (Huang et al.,
1996, 1997b). An overexpression of 
 
 
 
p85 almost completely
impaired 5-MCDE–induced AP-1 activation (Fig. 4, b–d).
This inhibition was present at all the time points and doses
tested in Cl41 AP-1 
 
 
 
p85 mass1 cell (Fig. 4, c and d). All
these results clearly show that 5-MCDE induces AP-1 activa-
tion through a PI-3K–mediated signaling pathway.
 
Overexpression of dominant-negative mutant Akt blocked 
5-MCDE–induced AP-1 activation in Cl41 cells
 
The primary consequence of PI-3K activation is the phosphor-
ylation of PtdIns(4,5)P2 (PIP
 
2
 
) into PtdIns(3,4,5)P3 (PIP
 
3
 
),
which acts as a second messenger. PIP
 
3
 
 recruits Akt, a serine/
threonine kinase, to the plasma membrane by direct interac-
tion with its PH domain (Andjelkovic et al., 1997; Bellacosa
et al., 1998). At the membrane, Akt can be phosphorylated at
Serine 473 and Threonine 308, and thus be activated to ex-
hibit its biological effect (Vanhaesebroeck and Alessi, 2000).
From our previous work, it is known that Akt is one of PI-3K
Figure 2. 5-MCDE induces the transcription of AP-1 target genes. 
Cl41 cells were seeded into 100-mm dishes. After being cultured at 
37 C overnight, cells were treated with various concentrations of 
5-MCDE as indicated for 12 or 24 h. RNA was isolated as described 
in Materials and methods. (a) RT-PCR for cyclin D1 and  -actin were 
performed as described in Materials and methods. (b) Total RNA 
(15  g) was subjected to Northern blot analysis and hybridized to 
mouse MMP13 probe. The ethidium bromide staining of the upper 
ribosomal subunit is the control to ensure equal RNA loading.
Figure 3. Induction of PI-3K activity by 5-MCDE in Cl41 cells. 
Cl41 cells were seeded into each of 100-mm dishes. The media 
were replaced with 0.1% FBS MEM after the cell density reached 
70–80% confluency. 45 h later, the cells were incubated with fresh 
serum-free MEM for 3–4 h at 37 C. Cells were exposed to 1  M 
5-MCDE for 20 min. Cells were washed once with ice-cold PBS and 
lysed in 400  l of lysis buffer. PI-3K activity was measured as 
described in Materials and methods. 
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downstream kinases in Cl41 cells in response to UV radiation
(Huang et al., 2001). However, it is not clear whether or not
Akt is activated by 5-MCDE. Also, there is no evidence to
show if Akt is required for AP-1 activation. To determine the
potential involvement of Akt in 5-MCDE–induced AP-1 ac-
tivation, we first compared the phosphorylation levels of Akt
at Thr308 and Ser473 in Cl41 AP-1 
 
 
 
p85 mass1 with those
in Cl41 AP-1 mass1 after 5-MCDE exposure. In Cl41 AP-1
mass1 cells, there were obvious increases of phosphorylations
at Akt Ser473 and Thr308 at different time points after
5-MCDE exposure, whereas in Cl41 AP-1 
 
 
 
p85 mass1 cells,
which express dominant-negative p85, the phosphorylations
at Akt Ser473 and Thr308 were completely impaired (Fig. 5).
Together with the data on AP-1 induction after 5-MCDE ex-
posure in Cl41 AP-1 
 
 
 
p85 mass1 cells, it suggested that PI-
3K might induce AP-1 transactivity through Akt kinase. To
further explore the role of Akt in 5-MCDE–induced AP-1 ac-
tivation, we established a stable transfectant with the domi-
nant-negative mutant Akt, Cl41 AP-1 Akt-T308A/S473A
mass1. In contrast to the induction of phosphorylations of
Akt at Thr308 and Ser473 after 5-MCDE in the Cl41 AP-1
mass1 cell, the expression of dominant-negative Akt-T308A/
S473A specifically blocked the increases of phosphorylations
of Akt at Thr308 and Ser473 (Fig. 6 a). Consistent with Akt
activation, in Cl41 DN Akt-T308A/S473A mass1 cells, c-Jun
phosphorylation and AP-1 activation were inhibited com-
Figure 4. Reduction of 5-MCDE–induced AP-1 activity by inhibition of PI-3K activation. 8   10
3 P
 1-1, Cl41 AP-1 mass1, or Cl41 AP-1 
 p85 mass1 were seeded into each well of 96-well plates. After being cultured at 37 C overnight, P
 1–1 cells were pretreated with various 
concentrations of wortmannin or Ly294002 as indicated for 30 min (a), and then exposed to 1  M 5-MCDE for 12 h. (b–d) Cl41 AP-1 mass1 
or Cl41 AP-1  p85 mass1 cells were treated with 1  M 5-MCDE for 12 h (b), 1  M 5-MCDE for various time points as indicated (c), or various 
concentrations of 5-MCDE for 12 h (d). The luciferase activity was measured and the results are presented as relative AP-1 activity. Each bar 
indicates the mean and SD of four repeat assay wells.
Figure 5. Effects of  p85 overexpression on 
phosphorylation of Akt and p70
S6K induced by 
5-MCDE. Subconfluent (90%) monolayers of Cl41 
AP-1 mass1 and Cl41 AP-1  p85 mass1 in 6-well 
plates were subjected to 1  M 5-MCDE for various 
periods of time as indicated. The cells were washed 
once with ice-cold PBS and extracted with SDS-
sample buffer. The cell extracts were separated on 
polyacrylamide–SDS gels, transferred, and probed 
with one of the specific antibodies as indicated. 
The protein band specific bound with primary 
antibodies was detected by using anti–rabbit 
IgG-AP-linked and ECF Western blotting system. 
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pared with that in Cl41 AP-1 mass4 cells (Fig. 6, b and c).
These results demonstrate that Akt is the downstream kinase
responsible for the activation of AP-1 by 5-MCDE.
 
p70
 
S6K
 
 is not involved in 5-MCDE–induced
AP-1 transactivation
 
Another important serine/threonine kinase related to PI-3K
and the Akt cascade is mTOR (the mammalian target of ra-
pamycin, also known as FRAP1), which regulates biosynthe-
sis by inhibiting 4E-BP1 and activating p70
 
S6K
 
 via phosphor-
ylation at its specific threonine and serine sites (Schmelzle
and Hall, 2000). There are many evidences showing that
mTOR is regulated directly by PI-3K (Brunn et al., 1996;
Nave et al., 1999). To explore the role of the mTOR–p70
 
S6K
 
cascade in AP-1 activation by 5-MCDE, we first measured
the level of the phosphorylated form of p70
 
S6K
 
 in exposed
cells. As shown in Fig. 5, there was an increase in phosphor-
ylation of p70
 
S6K
 
 at Thr389 and Thr421/Ser424 in Cl41
AP-1 mass1 cells after the exposure, whereas an introduction
of dominant-negative mutant PI-3K (
 
 
 
p85) only inhibited
5-MCDE–induced phosphorylation of p70
 
S6K
 
 in the early
phase (30 min after 5-MCDE exposure), but not at later
time points (Fig. 5, 120 or 300 min after exposure). Fur-
thermore, an overexpression of Akt-T308A/S473A did not
show any inhibitory effect on phosphorylation of p70
 
S6K
 
 at
Thr389 and Thr421/Ser424 (Fig. 6 a). This finding suggests
that 5-MCDE is able to induce p70
 
S6K
 
 phosphorylation at
Thr389 and Thr421/Ser424 through both PI-3K–depen-
dent and –independent pathways, and Akt activation is not
critical for p70
 
S6K
 
 activation in Cl41 cells. Furthermore, it
was found that inhibition of p70
 
S6K
 
 by pretreatment of cells
with rapamycin, a specific inhibitor for mTOR, did not
show any inhibitory effect on AP-1 transactivation induced
by 5-MCDE at various time points (Fig. 7). The results
indicate that 5-MCDE is able to activate p70
 
S6K
 
, however,
this activation is not required for AP-1 transactivation by
5-MCDE in mouse C141 cells.
 
Dominant-negative mutant Akt impaired 
5-MCDE–induced AP-1 activation specifically 
through inhibition of activation of ERKs and 
c-Jun NH
 
2
 
-terminal kinases (JNKs)
 
AP-1 has been identified as a target of the MAPKs family,
including ERKs, JNKs, and p38K (Karin et al., 1997). To
understand the interaction between MAPKs and PI-3K
on the regulation of AP-1 transactivation, the effects of
Figure 6. Effects of overexpression of AktT308A/S473A on 
5-MCDE–induced AP-1 activity and c-Jun phosphorylation. (a and b) 
For assay of phosphorylation of Akt, p70
S6K, or c-Jun, subconfluent 
(90%) monolayers of Cl41 AP-1 mass4 or Cl41 AP-1 DN-Akt T308A/
S473A in 6-well plates were subjected to 1  M 5-MCDE for 180 min 
(a) or time periods as indicated (b). The cells were extracted and 
Western blot was performed with specific antibodies as indicated. 
(c) 8   10
3 of Cl41 AP-1 mass4 or Cl41 AP-1 DN-Akt T308A/S473A 
were seeded into each well of 96-well plates. After being cultured at 
37 C overnight, the cells were exposed to 1  M 5-MCDE for various 
time points as indicated. The luciferase activity was measured and 
the results are presented as relative AP-1 activity. Each bar indicates 
the mean and SD of four repeat assay wells.
Figure 7. Inhibition of mTOR-p70
S6K pathway by rapamycin does 
not affect 5-MCDE–induced AP-1 transactivation. 8   10
3 P
 1-1 cells 
were seeded into each well of a 96-well plate. After being cultured 
at 37 C overnight, cells were pretreated with 20  M rapamycin for 
30 min and exposed to 1  M 5-MCDE for various time points as 
indicated. The luciferase activity was measured and the results are 
presented as relative AP-1 activity. Each bar indicates the mean and 
SD of four repeat assay wells. 
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5-MCDE on phosphorylations of the MAPKs were evaluated
in the cell transfected with dominant-negative mutant Akt,
Akt-T308A/S473A. Consistent with AP-1 induction, expo-
sure of Cl41 cells to 5-MCDE led to an increase in the phos-
phorylations of all three members of MAPKs, the ERKs,
JNKs, and p38K (Fig. 8 a). However, an overexpression of
dominant-negative mutant Akt, Akt-T308A/S473A, spe-
cifically inhibited 5-MCDE–induced phosphorylations of
ERKs and JNKs but not p38K (Fig. 8 a). To further in-
vestigate the role of ERKs and JNKs in 5-MCDE–induced
AP-1 activation, well-characterized dominant-negative mu-
tant ERK2 (Cl41 MAPK-DN B3 mass1) or JNK1 Cl41 cell
stable transfectants (Huang et al., 1999a,b) were used. As
shown in Fig. 8 b, overexpression of dominant-negative mu-
tant ERK2 or JNK1 markedly inhibited AP-1 activation by
5-MCDE. All these data show that Akt mediates AP-1 acti-
vation by 5-MCDE specifically through ERKs and JNKs
but not p38K.
 
Discussion
 
PAH contamination gets worldwide concerns for its impact
on human health and living environment. Exposures to PAHs
are associated with an increased risk of cancers in various or-
gans and tissues, including lung and skin (Hecht et al., 1974;
International Agency for Research on Cancer, 1983; Bernelot-
Moens et al., 1990; Amin et al., 1991; You et al., 1994; Nes-
now et al., 1998). 5-MCDE, the PAH studied in this paper, is
an in vivo metabolite of 5-methylchrysene, which has been
shown to be a complete carcinogen in laboratory animals
(Hecht et al., 1974; Amin et al., 1991; You et al., 1994).
Similar to the activation of B[a]P, 5-methylchrysene is
metabolized into its active epoxide metabolite in the skin
by CYP1A1 and CYP1B1 through the following pathway:
5-methylchrysene
 
→
 
1,2-dihydroxy-5-methylchrysene
 
→
 
5-
MCDE (Shimada et al., 2001). Previous studies have focused
on the mutagenicity of 5-MCDE, which is largely due to the
reactivity of 5-MCDE with DNA. Different from the weak
mutagenicity of the epoxide metabolites of other methylchry-
sene derivatives, 5-MCDE is a strong mutagen due to its
methyl group locating in the bay region. Thus, it binds to the
N2-guanosine site by a special stereo-structure, forming ad-
ducts similar to those derived from B[a]PDE (Melikian et al.,
1984; Amin et al., 1985; Hecht et al., 1987; Reardon et al.,
1987). These 5-MCDE–guanosine adducts cause subsequent
mutations and may activate k-ras oncogene and/or inactivate
tumor suppressor gene p53 (You et al., 1994; Denissenko et
al., 1996). In this paper, we present additional evidence that
5-MCDE may contribute to tumorigenesis by inducing AP-1
transactivation through PI-3K, Akt, MAPK, and JNK cas-
cades, which have been found to be required for tumor pro-
motion and progression.
AP-1 is an important transcription factor that governs the
expression of genes involved in intercellular communication,
amplification, and primary pathogenic signals spreading as
well as initiation and acceleration of tumorigenesis (Shaulian
and Karin, 2002). It recognizes both TPA response elements
(5
 
 -TGAG/CTCA-3 ) and cAMP response elements (5 -
TGACGTCA-3 ; Chinenov and Kerppola, 2001). The Cl41
cell line, which is used in this paper, proceeds to an anchorage-
independent growth phenotype and tumorigenicity upon the
induction by phobol ester (TPA), EGF, or TNF-  (Huang et
al., 1996, 1997b, 1999a; Watts et al., 1998). AP-1 activation
is identified as one of the required events for the aforemen-
tioned transformations (Colburn and Smith, 1987; Bernstein
and Colburn, 1989; Dong et al., 1994; Singh et al., 1995;
Huang et al., 1997a). Both the AP-1 molecular inhibitor
TAM67 (a transactivation domain deletion mutant of c-Jun)
and AP-1 transrepressing retinoids can block TPA-induced
AP-1 transactivation, cell transformation, and tumor induc-
tion (Dong et al., 1994; Huang et al., 1997a,b). Thus, the im-
portance of AP-1 in tumor promotion is well established. The
mechanisms of cell transformation by AP-1 are probably
through its manipulation on the target genes expressions
(Chinenov and Kerppola, 2001; Shaulian and Karin, 2001).
For instance, c-Jun is a positive regulator on gene expression of
cyclin D1 and FasL, and a negative regulator of p16
ink4a, p53,
and p21
cip1/waf1 (Shaulian and Karin, 2001), whereas c-Fos is
required for expression of many matrix metalloproteinases
Figure 8. 5-MCDE induces AP-1 activation through Akt-ERK and 
JNK pathway. (a) Subconfluent (90%) monolayers of Cl41 AP-1 
mass4 or Cl41 AP-1 DN-Akt T308A/S473A in 6-well plates were 
subjected to 1  M 5-MCDE for 90 min. The cells were extracted and 
Western blot was performed as described in Materials and methods 
with specific antibodies as indicated. (b) 8   10
3 Cl41 AP-1 Mass1, 
Cl41 MAPK-DN B3 mass1, or Cl41 DN-JNK1 mass2 were seeded into 
each well of 96-well plates. After being cultured at 37 C overnight, 
cells were exposed to 0.5  M 5-MCDE for 12 h. The luciferase 
activity was measured and the results are presented as relative AP-1 
activity. Each bar indicates the mean and SD of triplicate assay wells.Role of Akt in AP-1 activation by 5-MCDE | Li et al. 83
(Saez et al., 1995). In this paper, 5-MCDE was shown to in-
duce AP-1 transactivation. Although it does not change the
c-Fos protein level, 5-MCDE exposure increases the expres-
sions of Jun B, Fos B, Fra-1, and Fra-2. More importantly, the
phosphorylations of c-Jun protein at serines 63 and 73 are
markedly induced after 5-MCDE treatment. Furthermore,
5-MCDE exposure also increases the expression of AP-1 target
genes, such as cyclin D1 and collagenase type I, which are as-
sociated with cell cycle regulation and tumor induction, re-
spectively (Schonthal et al., 1988; Saez et al., 1995; Shaulian
and Karin, 2002). Because 5-MCDE is identified as a com-
plete carcinogen in animal carcinogenesis models, our results
strongly suggest that AP-1 activation is one of the events nec-
essary for the tumor promotion by 5-MCDE.
In the process of identifying the upstream-regulating sig-
nal transduction pathway, we found that the PI-3K path-
way is involved in 5-MCDE–induced AP-1 activation. Us-
ing both PI-3K inhibitor (wortmannin and LY294002)
and the dominant-negative mutant PI-3K ( p85) can
substantially inhibit AP-1 transactivation induced by
5-MCDE. This result is consistent with our previous find-
ings that PI-3K activation is the upstream kinase event re-
sponsible for mediation of AP-1 transactivation induced by
TPA or EGF (Huang et al., 1996, 1997b). PI-3K also plays
an important role in skin tumor progression phase. It is
suggested by the observations that wortmannin and domi-
nant-negative p85 subunit of PI-3K inhibit the TPA- and
EGF-induced cell transformation and prevent the invasion
of MDA-MB-435 cells, whereas a constitutively active
p110 subunit of PI-3K increases their invasion (Huang et
al., 1996, 1997b; Adelsman et al., 1999). Together, we
speculate that the PI-3K signal pathway is involved in car-
cinogenic effects of 5-MCDE.
Among the downstream kinases of PI-3K, Akt has been
identified as the main signal transmitter. Akt, which is also
known as PKB, is the cellular homologue of the retroviral on-
cogene v-Akt (Datta et al., 1999; Scheid and Woodgett,
2001). The activation of Akt has been identified in many
cancers (Cheng et al., 1996; Bellacosa et al., 1998; Ruggeri et
al., 1998; Shayesteh et al., 1999). For instance, amplification
of Akt was observed in cancers of the breast, ovaries, and pan-
creas (Cheng et al., 1996; Bellacosa et al., 1998; Ruggeri et
al., 1998; Shayesteh et al., 1999). The loss of function of tu-
mor suppressor gene PTEN, which converts PIP3 back to
PIP2 and thus mitigates the effects of Akt activation caused
by PI-3K, is also seen in a wide spectrum of human cancers
(Ali et al., 1999). Besides the PI-3K–dependent pathway, in-
creased calcium can also activate the calcium/calmodulin-
dependent kinase kinase, which then activates Akt by directly
phosphorylating Akt at the Thr
308 (Chen et al., 2002). In this
work, Akt was found to be involved in 5-MCDE–induced
AP-1 transactivation and activated in a PI-3K–dependent
manner. Overexpression of a dominant-negative subunit of
PI-3K blocked the 5-MCDE–induced Akt phosphorylations
at Ser473 and Thr308. Introduction of dominant negative
mutant Akt specifically impairs 5-MCDE–induced activa-
tion of AP-1. These results indicate that 5-MCDE induces
AP-1 activation through the PI-3K–Akt pathway.
The role of another possible PI-3K downstream signaling
pathway, mTOR–p70
S6K, in 5-MCDE–induced AP-1 acti-
vation was also investigated. Although the exact relation-
ship between mTOR and PI-3K remains to be determined,
mTOR has been found to be phosphorylated and activated
by Akt in mitogen-simulated cells and PTEN-deficient cells
(Brunet et al., 1999; Scheid and Woodgett, 2001). More-
over, application of an mTOR inhibitor had antiprolifera-
tive and anticancer effects in PTEN-deficient cells (White,
1998; Laine et al., 2000). mTOR controls the mammalian
translation machinery by activating p70
S6K, which enhances
the translation of mRNA with 5  polypyrimidine tracts, as
well as by inhibiting 4E-BP1 (also known as PHAS-1),
which is a translation inhibitor binding to the CAP struc-
ture present at the 5  termini of mRNAs (Thomas and
Hall, 1997; Hara et al., 1998). Currently, the mTOR deriv-
ative CCI-779 has entered a clinical trial for cancer treat-
ment (Mills et al., 2001; Owa et al., 2001). However, we
found mTOR is not involved in the 5-MCDE–induced
AP-1 activation pathway in Cl41 cells. This notion was
supported by the following evidence: (a) rapamycin can’t
decrease the 5-MCDE–induced AP-1 activation; (b) domi-
nant-negative mutant p85 impaired 5-MCDE–induced
AP-1 activation of all time points tested, and it only inhib-
ited the early phase but not the late phase of p70
S6K phos-
phorylation; and (c) overexpression of dominant-negative
mutant Akt impairs AP-1 activation, but not p70
S6K phos-
phorylation by 5-MCDE.
Besides the PI-3K pathway, MAPKs (ERKs, p38K, and
JNKs) are also found to involve in AP-1 activation by many
other stimuli. Serum and growth factors activate AP-1 tran-
scriptional activity mainly through ERKs, whereas the in-
duction of AP-1 by proinflammatory cytokines and geno-
toxic stress is mostly through activating JNKs and p38K
cascades (Gruda et al., 1994; Hill et al., 1994; Chang and
Karin, 2001). In this work, we demonstrated that PI-3K–
Akt pathway mediated AP-1 activation specifically through
activation of ERKs and JNKs. Although our most current
data have shown that p38K are activated and involved in
5-MCDE–induced AP-1 activation (unpublished data), the
signaling pathways leading to activation of p38K are still un-
der investigation in our laboratory.
In summary, the present work demonstrates that
5-MCDE induces AP-1 activity in a dose- and time-depen-
dent manner. AP-1 activation by 5-MCDE is mediated
through a PI-3K/Akt/ERKs, JNKs-dependent, and mTOR-
independent pathway. This conclusion is based on the re-
sults provided from using chemical inhibitors, including
wortmannin, Ly294002, and rapamycin, or overexpression
of dominant-negative mutants, such as  p85, Akt-T308A/
S473A, DN-ERK2, and DN-JNK1. This paper is highly rel-
evant to the understanding of the molecular mechanisms in-
volved in tumor promotion effects by 5-MCDE, but may
also provide some useful information for cancer chemopre-
vention by enabling manipulation of the upstream regula-
tory signal pathways leading to AP-1 activation. Although
mechanisms underlying the initiating signaling pathways by
5-MCDE are not well understood, we anticipate that oxida-
tive stress, such reactive oxygen species, may be involved.
This notion is supported by findings that 5-MCDE is capa-
ble of inducing oxidative DNA damage. Investigations are
underway to determine if this is the case.84 The Journal of Cell Biology | Volume 165, Number 1, 2004
Materials and methods
Plasmids and reagents
CMV-neo vector plasmid, Akt mutant plasmid (SR -Akt-T308A/S473A),
dominant-negative mutant PI-3K ( p85), ERK2, and JNK1 plasmids were as
described previously (Huang et al., 1996, 1997b, 1999a,b). The substrate
for the luciferase assay was purchased from Promega; 5-MCDE was syn-
thesized as described previously (Amin et al., 1985) and dissolved in
DMSO to give a stock concentration at 2 mM. The phosphospecific anti-
bodies against various phosphorylated sites of ERKs, p38K, and JNKs
were obtained from New England Biolabs, Inc. FBS and MEM were pur-
chased from BioWhittaker. The luciferase assay substrate was bought
from Promega. Phosphospecific p70
S6K (Thr
389) antibody, phosphospecific
p70
S6K (Thr
421/Ser
424) antibody, p70
S6K antibody phosphospecific Akt
(Thr308) antibody, phosphospecific Akt (Ser473) antibody, and Akt anti-
body were obtained from New England Biolabs, Inc. The antibodies to
Fra-1, Fra-2, Fos B, Jun B, and Jun D were obtained from Santa Cruz Bio-
technology, Inc. The PI-3K inhibitors, wortmannin, and Ly294002 and the
mTOR pathway inhibitor rapamycin were procured from Calbiochem. Li-
pofectAMINE was obtained from GIBCO BRL.
Cell culture
The JB6 P
  mouse epidermal Cl41 cell line and its transfectants were cul-
tured in monolayers at 37 C, 5% CO2, using MEM that contained 5% FBS,
2 mM L-glutamine, and 25  g gentamicin per milliliter as described previ-
ously (Huang et al., 1997a, 1998; Watts et al., 1998). The cultures were
dissociated with trypsin and transferred into new 75-cm
2 culture flasks
(Fisher Scientific) from one to three times per week.
Generation of stable cotransfectants
Cl41 cells were cultured in a 6-well plate until they reached 85–90% con-
fluence. 1  g of CMV-neo vector and 20  l of LipofectAMINE reagent,
with 2  g of AP-1-luciferase reporter plasmid DNA, mixed with 12  g of
dominant-negative mutant (SR -Akt-T308A/S473A) or vector control were
used to transfect each well in the absence of serum. After 10–12 h, the me-
dium was replaced with 5% FBS MEM. Approximately 30–36 h after the
beginning of the transfection, the cells were digested with 0.033% trypsin,
and cell suspensions were plated into 75-ml culture flasks and cultured for
24–28 d with G418 selection (400  g/ml). The all stable clones (stable
pool) in a flask were designed as a mass culture. The stable transfectants
were identified by measuring both the basal level of luciferase activity and
the blocking Akt activation. Stable transfectants, Cl41 AP-1 mass4 and
Cl41 AP-1 Akt-T308A/S473A mass1, were established and cultured in
G418-free MEM for at least two passages before each experiment.
AP-1 activity assay
Confluent monolayers of P
 1-1 cells or Cl41 cell stable transfectants were
trypsinized, and 8   10
3 viable cells suspended in 100  l MEM supple-
mented with 5% FBS were added to each well of 96-well plates. Plates
were incubated at 37 C in a humidified atmosphere with 5% CO2 in air.
After the cell density reached 80–90%, cells were exposed to 5-MCDE at a
final concentration as indicated in the figures for AP-1 induction. At differ-
ent periods after treatment, the cells were extracted with lysis buffer
(Promega) and their luciferase activity was determined by the Luciferase
assay using a luminometer (Wallac 1420 Victor 2 multilable counter sys-
tem; PerkinElmer) after the addition of 100  l of lysis buffer for 30 min at
4 C. The results are expressed as AP-1 activity relative to control medium
containing the same concentration of DMSO only (relative AP-1 activity).
Northern blot
Whole RNA was extracted from monolayer cells with TRIzol
® reagent ac-
cording to the manufacturer’s instructions (Invitrogen). 15  g RNA was run
on a 1% agarose/formaldehyde gel at 120 V for 1.5 h. The RNA was trans-
ferred to a nylon membrane (Ambion) by vacuum for 1.5 h and cross-
linked by UV wave. The murine collagenase I (MMP13) probe was PCR-
amplified from mouse mRNA (Yu et al., 2002). The probe was labeled with
 -[
32P]dCTP using Prime-a-Gene Labeling System (Promega). The radioac-
tivity was detected by phosphoImager using a scanner (model Storm™
860; Molecular Dynamics).
RT-PCR
The RNA was extracted by the Trizol
® method mentioned in the previous
paragraph. The cDNA was synthesized from 2  g RNA using First-Strand
Synthesis System for RT-PCR according to manufacturer’s instructions (In-
vitrogen). 1  l of synthesized cDNA was used for following multiplex PCR.
The murine cyclin D1 (Klein et al., 2003) and  -actin (sense, 5 -CCT GTG
GCA TCC ATG AAA CT-3 ; antisense, 5 -GTG CTA GGA GCC AGA GCA
GT-3 ) primers were added together and PCR-amplified for 21 cycles. The
PCR products were separated on 2% agarose gel.
PI-3K assay
PI-3K activities were assayed as described previously (Huang et al., 1996,
1997b). In brief, cells were cultured in monolayers in 100-mm dishes us-
ing normal culture medium. The media were replaced with 0.1% FBS
MEM that contained 2 mM L-glutamine and 25  g of gentamicin per milli-
liter after the cell density reached 70–80%. 45 h later, the cells were incu-
bated with fresh serum-free MEM medium for 3–4 h at 37 C. 5-MCDE was
added to cell cultures for PI-3K induction. Cells were washed once with
ice-cold PBS and lysed in 400  l of lysis buffer per plate (20 mM Tris, pH
8, 137 mM NaCl, 1 mM MgCl2, 10% glycerol, 1% NP-40, 1 mM dithio-
threitol, 0.4 mM sodium orthovanadate, and 1 mM PMSF). The lysates
were centrifuged and the supernatants incubated at 4 C with 40  l of aga-
rose beads (previously conjugated with the monoclonal anti-phosphoty-
rosine antibody Py20) overnight. Beads were washed twice with each of
the following buffers: (1) PBS with 1% NP-40 and 1 mM dithiothreitol; (2)
0.1 M Tris, pH 7.6, 0.5 M LiCl, and 1 mM dithiothreitol; and (3) 10 mM
Tris, pH 7.6, 0.1 M NaCl, and 1 mM dithiothreitol. Beads were incubated
for 5 min on ice in 20  l of buffer 3, and 20  l of 0.5 mg/ml phosphatidyl-
inositol (previously sonicated in 50 mM Hepes, pH 7.6, 1 mM EGTA, and
1 mM NaH2PO4) were added. After 5 min at RT, 10  l of the reaction
buffer were added (50 mM MgCl2, 100 mM Hepes, pH 7.6, and 250  M
ATP containing 5  Ci of  -[
32P]ATP), and beads were incubated for an ad-
ditional 15 min. Reactions were stopped by adding 15  l 4 N HCl and 130
 l of chloroform/methanol (1:1). After vortexing for 30 s, 30  l from the
phospholipid-containing chloroform phase were spotted onto TLC plates
coated with silica gel H containing 1.3% potassium oxalate and 2 mM
EDTA applied in H2O/methanol (3:2). Plates were heated at 110 C for at
least 3 h before use. Plates were placed in tanks containing chloroform/
methanol/NH4OH/H2O (600:470:20:113) for 40–50 min until the solvent
reached the top of the plates. Plates were dried at RT and autoradio-
graphed (Huang et al., 1996, 1997b).
Western blot
3   10
4 Cl41 transfectants were cultured in each well of 6-well plates to
70–80% confluence with normal culture medium. The cell culture me-
dium was replaced with 0.1% FBS MEM supplemented with 2 mM L-glu-
tamine and 25  g gentamicin per milliliter and cultured for 33 h. Cells
were incubated in serum-free MEM for 3–4 h at 37 C, and were then ex-
posed to 5-MCDE for various lengths of time. Cells were washed once
with ice-cold PBS and extracted with SDS-sample buffer. The cell extracts
were separated on polyacrylamide–SDS gels, transferred, and probed with
one of the specific antibodies as indicated. The protein bands specifically
bound to primary antibodies were detected using an anti–rabbit IgG-AP-
linked and an ECF Western blotting system (Huang et al., 2002; Amer-
sham Biosciences).
Statistical analysis
t test was used to determine the significance of differences in AP-1 activi-
ties between 5-MCDE treated and DMSO control. The differences were
considered significant at a P   0.05.
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